<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Echothiophate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Echothiophate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Echothiophate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9398" href="/d/html/9398.html" rel="external">see "Echothiophate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11636" href="/d/html/11636.html" rel="external">see "Echothiophate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F164017"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Phospholine Iodide</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1010366"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Ophthalmic Agent, Antiglaucoma</span>;</li>
<li>
<span class="list-set-name">Ophthalmic Agent, Miotic</span></li></ul></div>
<div class="block dop drugH1Div" id="F3017789"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abebef90-bfa0-457c-a90e-95f278a55523">Esotropia, accommodative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esotropia, accommodative:</b> Children and Adolescents: Ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">Diagnosis: Instill 1 drop once daily into both eyes at bedtime for 2 to 3 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment: Instill 1 drop every other day in both eyes; gradually lower dose as treatment progresses. Maximum daily dose: 1 drop once daily in both eyes. <b>Note:</b> Use lowest frequency which gives satisfactory response; if necessary, more aggressive therapy may be used for short periods of time.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51107950"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51107951"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F164018"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9398" href="/d/html/9398.html" rel="external">see "Echothiophate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60f91e7f-5b7f-4b65-8d79-2634ab361d31">Elevated intraocular pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Elevated intraocular pressure: Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial: Instill 1 drop in affected eye(s) twice daily (prior to bedtime and in the morning).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: Twice-daily dosing is preferred, but some patients have been treated with once-daily or every-other-day dosing (with 1 dose just prior to bedtime).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990086"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doha drugH1Div" id="F50987364"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block adr drugH1Div" id="F163999"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac abnormality (including bradycardia) (Manoguerra 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (Alexander 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (Manoguerra 1995), diarrhea (Alexander 1981), nausea (Manoguerra 1995), salivation (Manoguerra 1995), vomiting (Manoguerra 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (Alexander 1981), headache (Chamberlain 1974), myasthenia (Manoguerra 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Angle-closure glaucoma (Jones 1967), cataract (Shaffer 1966), iris cyst (Chamberlain 1974), lacrimation (Manoguerra 1995), miosis (Manoguerra 1995), myopia (Shaffer 1966)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (Manoguerra 1995)</p></div>
<div class="block coi drugH1Div" id="F164010"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to echothiophate or any component of the formulation; most cases of angle-closure glaucoma without iridectomy (due to possibility of increasing angle block); active uveal inflammation</p></div>
<div class="block war drugH1Div" id="F163996"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac irregularities: Temporarily or permanently discontinue if cardiac irregularities occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholinergic effects: Discontinue if symptoms of excess cholinergic activity (eg, salivation, sweating, urinary incontinence); overdosage may result in cholinergic crisis, which must be distinguished from myasthenic crisis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Not generally recommended for use in patients with asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Not generally recommended for use in patients with bradycardia, hypotension or recent MI. In a scientific statement from the American Heart Association, ophthalmic cholinergic agents have been determined to be agents that may exacerbate underlying myocardial dysfunction (magnitude: minor) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Not generally recommended for use in patients with spastic gastrointestinal disturbances or peptic ulcer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinsonism: Not generally recommended for use in patients with Parkinsonism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Not generally recommended for use in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vagotonia: Not generally recommended for use in patients with vagotonia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not use for tonometric glaucoma, or in patients with active or history of uveitis, or history of retinal detachment. Use cautiously prior to ophthalmic surgery due to risk of blood in the anterior chamber. Digital compression of the nasolacrimal ducts for 1 to 2 minutes following instillation to minimize drainage into the nasal chamber is recommended. Wash hands following instillation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Exposure to pesticides and insecticides: Use with caution in patients exposed to carbamate- or organophosphate-type insecticides and pesticides; absorption of the pesticide through skin or respiratory tract may result in additive systemic effects; respiratory masks and frequent clothing changes may be necessary during exposure to pesticides in patients receiving echothiophate iodide.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Patients may develop tolerance after prolonged use; a rest period restores response to the drug.</p></div>
<div class="block foc drugH1Div" id="F164005"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phospholine Iodide: 0.125% (5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phospholine Iodide: 0.125% (5 mL) [contains chlorobutanol (chlorobutol)]</p></div>
<div class="block geq drugH1Div" id="F163992"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F164012"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Phospholine Iodide Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125% (per mL): $611.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612662"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For ophthalmic use only. Proper administration technique is required for maximal benefit. Wash hands prior to use; to avoid contamination, do not allow dispenser tip to touch the eye or any surface; apply gentle pressure to the nasolacrimal duct(s) for 1 to 2 minutes after instillation of the drops to minimize drainage into nose and throat. Excess fluid around the eye should be blotted with tissue; wash hands after instillation.</p></div>
<div class="block adm drugH1Div" id="F3017790"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Ophthalmic: Proper administration technique is required for maximal benefit. The nasolacrimal duct(s) should be compressed for 1 to 2 minutes after instillation of the drops. Excess fluid around the eye should be blotted with tissue; wash hands after instillation.</p></div>
<div class="block sts drugH1Div" id="F164016"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store undiluted vials at 2°C to 8°C (36°F to 46°F). Store reconstituted solutions at ~25°C (~77°F); do not refrigerate; discard unused solution after 4 weeks. </p></div>
<div class="block usep drugH1Div" id="F53566629"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Diagnosis and treatment of accommodative esotropia (FDA approved in pediatric patients [age not specified]); treatment of chronic open-angle glaucoma; subacute or chronic angle-closure glaucoma (postiridectomy or where surgery is refused or contraindicated); certain nonuveitic secondary types of glaucoma, especially glaucoma following cataract surgery (FDA approved in adults)</p></div>
<div class="block cyt drugH1Div" id="F13299249"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F3017787"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cyclopentolate: May diminish the therapeutic effect of Echothiophate Iodide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Echothiophate Iodide may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Echothiophate Iodide may increase the serum concentration of Succinylcholine.  Management: For patients receiving echothiophate iodide eye drops, consider using a neuromuscular-blocking agents other than succinylcholine. If succinylcholine is used, consider a reduced dose, and monitor for enhanced/prolonged effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tropicamide: May diminish the therapeutic effect of Echothiophate Iodide.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F3017784"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Animal reproduction studies have not been conducted. </p></div>
<div class="block mopp drugH1Div" id="F53566622"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline measurement of anterior chamber angle; routine lens examinations (for opacities and during treatment of accommodative esotropia); IOP (at different times of the day)</p></div>
<div class="block pha drugH1Div" id="F163995"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Long-acting inhibition of cholinesterase enhances activity of endogenous acetylcholine. Reduced degradation of acetylcholine leads to continuous stimulation of  the ciliary muscle producing miosis; other effects include potentiation of accommodation and facilitation of aqueous humor outflow, with attendant reduction in intraocular pressure.</p></div>
<div class="block phk drugH1Div" id="F164009"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Miosis: ≤60 minutes</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peak effect: Intraocular pressure decrease: After 24 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Miosis: 1 to 4 weeks; Intraocular pressure: Days to weeks. </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038607"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Oftan eco</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Phospholine Iodide</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-14123459">
<a name="14123459"></a>Abrahamson IA Jr, Abrahamson IA Sr. Prelimary report on 0.06-percent phospholine (echothiophate) iodide in the management of esotropia. <i>Am J Ophthalmol</i>. 1964;57:290-298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/14123459/pubmed" id="14123459" target="_blank">14123459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6786494">
<a name="6786494"></a>Alexander WD. Systemic side effects with eye drops. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6273):1359. doi:10.1136/bmj.282.6273.1359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/6786494/pubmed" id="6786494" target="_blank">6786494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5640850">
<a name="5640850"></a>Birks DA, Prior VJ, Silk E, et al, "Echothiophate Iodide Treatment of Glaucoma in Pregnancy," <i>Arch Ophthalmol</i>, 1968, 79(3):283-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/5640850/pubmed" id="5640850" target="_blank">5640850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4462244">
<a name="4462244"></a>Chamberlain W. Anticholinesterase miotics in the management of accommodative esotropia. <i>Trans Am Ophthalmol Soc</i>. 1974;72:229-241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/4462244/pubmed" id="4462244" target="_blank">4462244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6060809">
<a name="6060809"></a>Jones DE, Watson DM. Angle-closure glaucoma precipitated by the use of phospholine iodide for esotropia in a child. <i>Br J Ophthalmol</i>. 1967;51(11):783-785. doi:10.1136/bjo.51.11.783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/6060809/pubmed" id="6060809" target="_blank">6060809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7650771">
<a name="7650771"></a>Manoguerra A, Whitney C, Clark RF, Anderson B, Turchen S. Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. <i>J Toxicol Clin Toxicol</i>. 1995;33(5):463-465. doi:10.3109/15563659509013755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/7650771/pubmed" id="7650771" target="_blank">7650771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Phospholine iodide (echothiophate) [prescribing information]. Locust Valley, NY: Fera Pharmaceuticals LLC; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6007355">
<a name="6007355"></a>Shaffer RN, Hetherington J Jr. Anticholinesterase drugs and cataracts. <i>Trans Am Ophthalmol Soc</i>. 1966;64:204-216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/echothiophate-pediatric-drug-information/abstract-text/6007355/pubmed" id="6007355" target="_blank">6007355</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 106576 Version 56.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
